{"disease":{"id":"noonan-s-syndrome","name":"Noonan's syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"oxymesterone","indication_name":"Noonan's syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anamidol","generic_name":"OXYMESTERONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxymesterone","quality_score":null,"revenue":null,"mechanism":"Anamidol binds to androgen receptors in the body, triggering a cascade of downstream effects that promote muscle growth and development."},{"drug_id":"fluoxymesterone","indication_name":"Noonan's syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluotestin","generic_name":"FLUOXYMESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT04463316","title":"GROWing Up With Rare GENEtic Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"dr. Laura C. G. de Graaff-Herder","has_results":false},{"nct_id":"NCT04888936","title":"Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06938542","title":"Palliative Care Needs of Children With Rare Diseases and Their Families","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":480,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT06331117","title":"Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05361811","title":"Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}